Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial (Nature Medicine, (2024), 10.1038/s41591-024-03025-3)

Roger Li; Paras H. Shah; Tyler F. Stewart; Jong Kil Nam; Trinity J. Bivalacqua; Donald L. Lamm; Edward M. Uchio; Daniel M. Geynisman; Joseph M. Jacob; Joshua J. Meeks; Rian Dickstein; Shane M. Pearce; Seok Ho Kang; Seung Il Jung; Ashish M. Kamat; James M. Burke; Kirk A. Keegan; Gary D. Steinberg

doi:10.1038/s41591-024-03157-6

Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial (Nature Medicine, (2024), 10.1038/s41591-024-03025-3)

Roger Li
, Paras H. Shah
, Tyler F. Stewart
, Jong Kil Nam
, Trinity J. Bivalacqua
, Donald L. Lamm
, Edward M. Uchio
, Daniel M. Geynisman
, Joseph M. Jacob
, Joshua J. Meeks
, Rian Dickstein
, Shane M. Pearce
, Seok Ho Kang
, Seung Il Jung
, Ashish M. Kamat
, James M. Burke
, Kirk A. Keegan
, Gary D. Steinberg

Research output: Contribution to journal › Comment/debate

Abstract

Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-024-03025-3, published online 6 June 2024 In the version of the article initially published, in the key to Fig. 2b, the red diamond representing “Recurrence/NR” has been corrected to a green diamond to match the graph. This correction has been made to the HTML and PDF versions of the article.

Original language	English
Pages (from-to)	2377
Journal	Nature Medicine
Volume	30
Early online date	Jun 2 2024
DOIs	https://doi.org/10.1038/s41591-024-03157-6
State	Published - Jul 2 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/s41591-024-03157-6

Fingerprint

Dive into the research topics of 'Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial (Nature Medicine, (2024), 10.1038/s41591-024-03025-3)'. Together they form a unique fingerprint.

Cite this

Li, R., Shah, P. H., Stewart, T. F., Nam, J. K., Bivalacqua, T. J., Lamm, D. L., Uchio, E. M., Geynisman, D. M., Jacob, J. M., Meeks, J. J., Dickstein, R., Pearce, S. M., Kang, S. H., Jung, S. I., Kamat, A. M., Burke, J. M., Keegan, K. A., & Steinberg, G. D. (2024). Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial (Nature Medicine, (2024), 10.1038/s41591-024-03025-3). Nature Medicine, 30, 2377. https://doi.org/10.1038/s41591-024-03157-6

@article{6bca11c9d1684eb58c61d89fe14b296e,

title = "Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial (Nature Medicine, (2024), 10.1038/s41591-024-03025-3)",

abstract = "Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-024-03025-3, published online 6 June 2024 In the version of the article initially published, in the key to Fig. 2b, the red diamond representing “Recurrence/NR” has been corrected to a green diamond to match the graph. This correction has been made to the HTML and PDF versions of the article.",

author = "Roger Li and Shah, \{Paras H.\} and Stewart, \{Tyler F.\} and Nam, \{Jong Kil\} and Bivalacqua, \{Trinity J.\} and Lamm, \{Donald L.\} and Uchio, \{Edward M.\} and Geynisman, \{Daniel M.\} and Jacob, \{Joseph M.\} and Meeks, \{Joshua J.\} and Rian Dickstein and Pearce, \{Shane M.\} and Kang, \{Seok Ho\} and Jung, \{Seung Il\} and Kamat, \{Ashish M.\} and Burke, \{James M.\} and Keegan, \{Kirk A.\} and Steinberg, \{Gary D.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Nature America, Inc. 2024.",

year = "2024",

month = jul,

day = "2",

doi = "10.1038/s41591-024-03157-6",

language = "English",

volume = "30",

pages = "2377",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Research",

}

Li, R, Shah, PH, Stewart, TF, Nam, JK, Bivalacqua, TJ, Lamm, DL, Uchio, EM, Geynisman, DM, Jacob, JM, Meeks, JJ, Dickstein, R, Pearce, SM, Kang, SH, Jung, SI, Kamat, AM, Burke, JM, Keegan, KA & Steinberg, GD 2024, 'Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial (Nature Medicine, (2024), 10.1038/s41591-024-03025-3)', Nature Medicine, vol. 30, pp. 2377. https://doi.org/10.1038/s41591-024-03157-6

Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial (Nature Medicine, (2024), 10.1038/s41591-024-03025-3). / Li, Roger; Shah, Paras H.; Stewart, Tyler F. et al.
In: Nature Medicine, Vol. 30, 02.07.2024, p. 2377.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Publisher Correction

T2 - Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial (Nature Medicine, (2024), 10.1038/s41591-024-03025-3)

AU - Li, Roger

AU - Shah, Paras H.

AU - Stewart, Tyler F.

AU - Nam, Jong Kil

AU - Bivalacqua, Trinity J.

AU - Lamm, Donald L.

AU - Uchio, Edward M.

AU - Geynisman, Daniel M.

AU - Jacob, Joseph M.

AU - Meeks, Joshua J.

AU - Dickstein, Rian

AU - Pearce, Shane M.

AU - Kang, Seok Ho

AU - Jung, Seung Il

AU - Kamat, Ashish M.

AU - Burke, James M.

AU - Keegan, Kirk A.

AU - Steinberg, Gary D.

PY - 2024/7/2

Y1 - 2024/7/2

N2 - Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-024-03025-3, published online 6 June 2024 In the version of the article initially published, in the key to Fig. 2b, the red diamond representing “Recurrence/NR” has been corrected to a green diamond to match the graph. This correction has been made to the HTML and PDF versions of the article.

AB - Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-024-03025-3, published online 6 June 2024 In the version of the article initially published, in the key to Fig. 2b, the red diamond representing “Recurrence/NR” has been corrected to a green diamond to match the graph. This correction has been made to the HTML and PDF versions of the article.

UR - https://www.scopus.com/pages/publications/85197413580

U2 - 10.1038/s41591-024-03157-6

DO - 10.1038/s41591-024-03157-6

M3 - Comment/debate

C2 - 38956199

AN - SCOPUS:85197413580

SN - 1078-8956

VL - 30

SP - 2377

JO - Nature Medicine

JF - Nature Medicine

ER -

Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial (Nature Medicine, (2024), 10.1038/s41591-024-03025-3)

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this